Method for suppressing regulatory t cell infiltration by ccr4 inhibition and method for treating canine neoplastic disease

Abstract

Provided are a treatment method and a therapeutic agent for canine tumor. A pharmaceutical composition for treating canine tumor, comprising, as an active ingredient, a compound that inhibits the binding of canine CCL17 and canine CCR4.

1 . A pharmaceutical composition for treating canine tumor, comprising, as an active ingredient, a compound that inhibits the binding of canine CCL17 and canine CCR4. 
     
     
         2 . The pharmaceutical composition according to  claim 1 , wherein the compound that inhibits the binding of canine CCL17 and canine CCR4 is an anti-CCR4 antibody. 
     
     
         3 . The pharmaceutical composition according to  claim 1 , wherein the compound that inhibits the binding of canine CCL17 and canine CCR4 is 2-[1,4′-bipiperidin]-1′-yl-N-cycloheptyl-6,7-dimethoxy-4-quinazolinamine dihydrochloride. 
     
     
         4 . The pharmaceutical composition according to  claim 1 , wherein the canine tumor is selected from the group consisting of transitional cell carcinoma, prostate cancer, breast cancer, malignant melanoma, squamous cell carcinoma, and pulmonary adenocarcinoma. 
     
     
         5 . The pharmaceutical composition according to  claim 4 , wherein the canine tumor is selected from the group consisting of transitional cell carcinoma, prostate cancer, and breast cancer. 
     
     
         6 . A method for treating canine tumor, comprising administering a compound that inhibits the binding of canine CCL17 and canine CCR4 to a dog in need thereof. 
     
     
         7 . The method according to  claim 6 , wherein the compound that inhibits the binding of canine CCL17 and canine CCR4 is an anti-CCR4 antibody. 
     
     
         8 . The method according to  claim 6 , wherein the compound that inhibits the binding of canine CCL17 and canine CCR4 is 2-[1,4′-bipiperidin]-1′-yl-N-cycloheptyl-6,7-dimethoxy-4-quinazolinamine dihydrochloride. 
     
     
         9 . The method according to  claim 6 , wherein the canine tumor is selected from the group consisting of transitional cell carcinoma, prostate cancer, breast cancer, malignant melanoma, squamous cell carcinoma, and pulmonary adenocarcinoma. 
     
     
         10 . The method according to  claim 9 , wherein the canine tumor is selected from the group consisting of transitional cell carcinoma, prostate cancer, and breast cancer. 
     
     
         11 . A method for predicting the efficacy of a compound that inhibits the binding of canine CCL17 and canine CCR4 on the treatment of canine tumor, using the level of CCL17 in a canine biological sample, wherein the compound is predicted to have high efficacy, when the CCL17 level in the biological sample is high. 
     
     
         12 . The method according to  claim 11 , wherein the canine biological sample is urine. 
     
     
         13 . The method according to  claim 11 , wherein the compound that inhibits the binding of canine CCL17 and canine CCR4 is an anti-CCR4 antibody. 
     
     
         14 . The method according to  claim 11 , wherein the compound that inhibits the binding of canine CCL17 and canine CCR4 is 2-[1,4′-bipiperidin]-1′-yl-N-cycloheptyl-6,7-dimethoxy-4-quinazolinamine dihydrochloride. 
     
     
         15 . The method according to  claim 11 , wherein the canine tumor is selected from the group consisting of transitional cell carcinoma, prostate cancer, breast cancer, malignant melanoma, squamous cell carcinoma, and pulmonary adenocarcinoma. 
     
     
         16 . The method according to  claim 15 , wherein the canine tumor is selected from the group consisting of transitional cell carcinoma, prostate cancer, and breast cancer.